Insider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) Director Buys 3,605 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano acquired 3,605 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was acquired at an average cost of $4.49 per share, with a total value of $16,186.45. Following the purchase, the director now owns 7,807 shares of the company’s stock, valued at approximately $35,053.43. This trade represents a 85.79 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

Precision BioSciences Price Performance

DTIL stock traded up $0.94 during midday trading on Thursday, hitting $4.75. The company’s stock had a trading volume of 117,533 shares, compared to its average volume of 86,169. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences, Inc. has a 12 month low of $3.61 and a 12 month high of $19.43. The company has a 50 day moving average of $6.59 and a two-hundred day moving average of $8.51. The firm has a market capitalization of $36.44 million, a price-to-earnings ratio of 79.18 and a beta of 1.41.

Hedge Funds Weigh In On Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC raised its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 702,069 shares of the company’s stock after buying an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned about 9.15% of Precision BioSciences worth $6,322,000 as of its most recent SEC filing. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.